IMMP - Immutep's eftilagimod alpha receives positive FDA feedback for late-stage development in NSCLC
2023-05-16 08:46:48 ET
- Immutep ( NASDAQ: IMMP ) announced that it received positive feedback from the US Food and Drug Administration regarding the its late-stage clinical development plans for eftilagimod alpha, a soluble LAG-3 protein and MHC Class II agonist, to treat first-line non-small cell lung cancer (NSCLC).
- ( IMMP ) is trading ~5% higher premarket.
- Based on the encouraging data from Phase II TACTI-002, Part A, the FDA has expressed support for a registrational trial to assess eftilagimod alpha in combination with an anti-PD-1 therapy for first-line non-small cell lung cancer patients, regardless of their PD-L1 expression levels.
- These interactions mark a significant milestone for Immutep, advancing its three major clinical programs aimed at addressing cancers that impact a substantial number of patients. This development positions eftilagimod alpha (efti) to have a profound impact on the lives of numerous patients who require improved, well-tolerated, and long-lasting immunotherapy treatments .
For further details see:
Immutep's eftilagimod alpha receives positive FDA feedback for late-stage development in NSCLC